ArticleEndocrine2026
MicroRNA signatures associated with radioiodine refractoriness and tumor dedifferentiation in metastatic papillary thyroid carcinoma.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRadioiodine (RAI) refractoriness and tumor dedifferentiation are major contributors to poor outcomes in metastatic papillary thyroid carcinoma (PTC). microRNAs (miRNAs) are promising biomarkers to identify these aggressive phenotypes. This study aimed to characterize miRNAs expression profiles associated with RAI refractoriness and dedifferentiation.
methodsFrom a cohort of 108 metastatic PTC patients, 24 cases with available formalin-fixed paraffin-embedded tissue were selected for molecular analysis, including 17 patients who died from disease progression and 7 long-term survivors with stable disease. Total RNA was extracted and analyzed by qPCR. miRNAs with differential expression (P < 0.10) in univariate analysis were included in multivariate linear regression models. Diagnostic performance was assessed using ROC curve analysis and hierarchical clustering.
resultsThe cohort had a mean age of 55.2 years and was predominantly male (66.7%). RAI-refractory disease was present in 63.2% of evaluable cases, and dedifferentiation in 33.3%. In multivariate analysis, lower expression of miR-200c-3p was independently associated with RAI refractoriness (P = 0.005). For tumor dedifferentiation, higher expression of let-7i-5p (P < 0.001) and miR-19b-3p (P < 0.001), and lower expression of miR-31-5p (P = 0.004) and let-7e-5p (P = 0.036), were independently associated. ROC curve analysis demonstrated high diagnostic accuracy for miR-200c-3p (AUC = 0.929) and let-7i-5p (AUC = 0.958) for, respectively, RAI refractoriness and tumor dedifferentiation. Heatmap analysis revealed clear segregation of phenotypic groups based on miRNA expression.
conclusionsDistinct miRNAs signatures are associated with RAI refractoriness and tumor dedifferentiation in metastatic PTC. These findings support their potential as prognostic biomarkers and may guide future therapeutic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.